
TDI01 Demonstrates Preliminary Efficacy and Tolerability in Moderate-to-Severe cGVHD
Treatment with TDI01—an oral, highly selective ROCK2 inhibitor—led to clinical activity and tolerability in patients with moderate-to-severe chronic graft-vs-host disease (cGVHD), according to findings from a phase 1b/2 study (NCT06169722) presented at …